Proteomic and Metabolomic Investigation of COVID-19 1 Patients with Elevated Serum Lactate Dehydrogenase 2

Haixi Yan^{1#}, Xiao Liang^{2,3,4#}, Juping Du^{1,#}, Zebao He^{1,#}, Yu Wang⁵, Mengge Lyu^{2,3,4}, Liang Yue^{2,3,4}, Fangfei Zhang^{2,3,4}, Zhangzhi Xue^{2,3,4}, Luang Xu^{2,3,4}, Guan Ruan⁶, Jun 3 4 Li¹, Hongguo Zhu¹, Jiaqin Xu¹, Shiyong Chen¹, Chao Zhang¹, Dongqing Lv¹, 5

- Zongmei Lin¹, Bo Shen¹, Yi Zhu^{2,3,4†}, Biyun Qian^{5,†}, Haixiao Chen^{1,†}, Tiannan 6 $Guo^{2,3,4\dagger}$
- 7
- ¹ Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, 8
- 150 Ximen Street, Linhai 317000, Zhejiang Province, China 9
- ² Key Laboratory of Structural Biology of Zhejiang Province, School of Life 10
- Sciences, Westlake University, 18 Shilongshan Road, Hangzhou 310024, Zhejiang 11
- Province, China 12
- ³ Center for Infectious Disease Research, Westlake Laboratory of Life Sciences and 13 Biomedicine, Hangzhou 310024, China 14
- ⁴ Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, 18 15 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China 16
- ⁵ Honggiao International Institute of Medicine, Shanghai Tongren Hospital and 17
- Faculty of Public Health, Shanghai Jiao Tong University School of Medicine, 18 Shanghai 200025, China 19
- ⁶ Westlake Omics (Hangzhou) Biotechnology Co., Ltd. No.1, Yunmeng Road, Cloud 20
- Town, Xihu District, Hangzhou, Zhejiang Province, China 21
- 22
- [#] These authors contributed equally to this study. 23
- [†]Correspondence and requests for materials should be addressed to Z.Y. 24
- (zhuyi@westlake.edu.cn), B.Q. (qianbiyun@sjtu.edu.cn), H.C. 25
- (chenhx@enzemed.com), and T.G. (guotiannan@westlake.edu.cn). 26

- Keywords: COVID-19; lactate dehydrogenase; proteomics; metabolomics; 28
- biomarker; prognosis 29
- 30

31 Abstract

Serum lactate dehydrogenase (LDH) has been established as a prognostic indicator 32 given its differential expression in COVID-19 patients. However, the molecular 33 mechanisms underneath remain poorly understood. In this study, 144 COVID-19 34 patients were enrolled to monitor the clinical and laboratory parameters over three 35 weeks. Serum lactate dehydrogenase (LDH) was shown elevated in the COVID-19 36 patients on admission and declined throughout disease course, and its ability to 37 classify patient severity outperformed other biochemical indicators. A threshold of 38 39 247 U/L serum LDH on admission was determined for severity prognosis. Next, we classified a subset of 14 patients into high- and low-risk groups based on serum LDH 40 expression and compared their quantitative serum proteomic and metabolomic 41 differences. The results found COVID-19 patients with high serum LDH exhibited 42 differentially expressed blood coagulation and immune responses including acute 43 inflammatory responses, platelet degranulation, complement cascade, as well as 44 multiple different metabolic responses including lipid metabolism, protein 45 ubiquitination and pyruvate fermentation. Specifically, activation of hypoxia 46 responses was highlighted in patients with high LDH expressions. Taken together, our 47 data showed that serum LDH levels are associated COVID-19 severity, and that 48 49 elevated serum LDH might be consequences of hypoxia and tissue injuries induced by inflammation. 50

52 **INTRODUCTION**

COVID-19 is an ongoing global pandemic caused by severe acute respiratory
 syndrome coronavirus 2 (SARS-CoV-2). A high viral transmission rate and the lack of
 effective therapy contributed to more than 83 million infected cases as of time January
 3rd, 2021 ^[1].

To better diagnose COVID-19 and monitor the disease progress, multiple molecules 57 have been proposed as prognostic indicators ^[2]. Lactate dehydrogenase (LDH) is an 58 intracellular enzyme, catalyzing pyruvate fermentation and facilitating glycolysis. 59 LDH is released into the blood after cell death and has been reported to increase in a 60 variety of diseases including Severe acute respiratory syndrome (SARS)^[3], diabetes 61 ^[4], and cancers ^[5]. Serum LDH levels in COVID-19 patients are over-expressed ^[2], 62 especially in severe and critical patients ^[6-9]. They decrease throughout disease course 63 ^[7,10], in correlation with viral mRNA clearance ^[7]. Related studies have shown that 64 serum LDH is well correlated with respiratory failure ^[11], lung injury, disease severity 65 ^[12] and mortality ^[13] in COVID-19 patients. 66

However, the molecular mechanisms underlying the LDH's association with the 67 COVID-19 disease progression remains poorly understood. Most studies attribute 68 serum LDH elevation to its release from somatic tissue and organ damage caused by 69 either viral attack ^[12] or inflammation ^[10]. These clinical assumptions lack molecular 70 evidence, potentially leading to biased assessments. Moreover, these explanations 71 failed to consider the metabolic role of LDH to balance excess lactate during hypoxia. 72 Here we have systematically explored the proteome and metabolome of sera from 73 COVID-19 patients with low and high serum LDH, and identified the specific host 74 75 responses, which shed light on the pathogenesis and convalesce of COVID-19.

76

77 MATERIALS AND METHODS

78 Patient Information

We collected and curated the electronic medical records of patient information in 79 80 Taizhou Hospital of Zheijang Province, between January 17 and February 20, 2020. 212 patients met the criteria of suspected COVID-19, of which 145 patients were 81 confirmed as COVID-19, based on the Government's Diagnosis and Treatment 82 Guideline (5th version)^[14].144 patients COVID-19 patients were included in this 83 study after excluding one patient who had incomplete laboratory data. According to 84 85 the admission period, we grouped them into two cohorts. Patients admitted to Taizhou Public Health Medical Center, Taizhou Hospital between January 17 and February 4, 86 2020 were included in the cohort 1 (n = 115). The cohort 2 (n = 29) contained 87 COVID-19 patients admitted from February 4 to February 20, 2020. The end of the 88 follow-up date was March 1, 2020. Disease severity was accessed according to the 89 90 abovementioned guideline. We classified COVID-19 patients into two groups (severe and non-severe): the severe group included severe and critical patients, and the non-91 severe group included mild and typical patients. Briefly, those who had shortness of 92 breath with respiratory rate ≥ 30 breaths/min, a ratio of arterial blood oxygen partial 93 pressure to oxygen concentration ≤ 300 mmHg or saturation of oxygen $\leq 93\%$ when 94 resting were defined as severe patients. The other COVID-19 patients were grouped 95 96 as non-severe patients. 125 healthy individuals were enrolled as controls. 97 This study was conducted in accordance with the Helsinki Declaration and was approved by the institutional medical ethics review boards of Taizhou Hospital of 98 99 Zhejiang Province and Westlake University (Approval ID: 20210119GTN001).

100 *Laboratory tests*

101 Samples were taken throughout disease course from patient admission to discharge. 102 More details are described in Supplementary Table 1. For laboratory tests, 404 serial 103 blood samples from 144 patients were collected and centrifuged at 1500 g for 10 min 104 at room temperature.

For serum of COVID-19 patients, seven biochemical indicators were tested, namely
lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine
aminotransferase (ALT), total bilirubin, total protein, creatinine, and creatine kinase
(CK), with a Chemistry Analyzer (Beckman Coulter, AU5821). The serum LDH was
measured for healthy controls.

For LDH isoform analyses, 32 serum samples from 32 COVID-19 patients (11 nonsevere and 21 severe) were sent for electrophoresis with agarose gel electrophoretic analyzer (SEBIA, HYDRASYS 2). ISO-LDH substrate and blocking buffer were afterwards added to incubate for 20 min, respectively. The gel was scanned with the same analyzer.

115

136

116 Proteomic and metabolomic data set

The proteomic and metabolomic data were extracted from our previous publication 117 ^[14]. Briefly, serum samples from COVID-19 patients were kept at 56°C for 30 min to 118 inactivate potential SARS-CoV-2. For proteomic experiments, inactivated serum 119 samples were processed into peptides, labeled with TMTpro 16plex chemical tags, 120 121 fractionated to 40 aliquots, and analyzed by LC-MS/MS. The proteomics data were analyzed with Proteome Discoverer (Version 2.4.1.15, Thermo Fisher Scientific), with 122 the default parameter and a protein database composed of the Homo sapiens fasta 123 database (07 Jan 2020, UniProtKB), containing 20,412 reviewed protein sequences, 124 and the SARS-CoV-2 virus fasta (version NC 045512.2, NCBI). Targeted false 125 discovery rate (FDR) for peptide-spectrum match was set to 1% (strict) and 5% 126 (relaxed). Normalization was performed against the total peptide intensity. 894 127 proteins were quantified altogether. For metabolomic experiments, inactivated serum 128 samples were processed to collect metabolites, and divided into 4 fractions for 4 129 different modes of LC-MS/MS data acquisition, leading to characterization of 941 130 metabolites. The median coefficient of variance (CV) for proteomic and metabolomic 131 data were 10% and 5%, respectively, determined by pooled control samples in each 132 batch, as described previously ^[14]. The proteomics and metabolomics data could be 133 referenced from the previously publication in ProteomeXchange Consortium 134 135 (https://www.iprox.org/). Project ID: IPX0002106000 and IPX0002171000.

137 Statistical analysis

Statistical clinical data analyses were performed using SPSS software (version 138 22.0). Continuous variables were presented as median and interquartile range (IQR) 139 values, while categorical variables were shown as frequency and percentage. An 140 independent t-test was used for continuous variables when the data were normally 141 distributed; otherwise, the Mann-Whitney test was used. Chi-square test or Fisher's 142 exact test was used for categorical variables. Receiver operating characteristic (ROC) 143 analysis was used for the selection of the best intercept point. Prediction of disease 144 progression was obtained using the Cox proportional hazards model. Statistical 145 proteomic data analysis was performed using R (version 3.6.3). Missing values in the 146 147 proteomic data matrix were assigned as 0.01 unless otherwise mentioned. P values \leq 0.05 were considered statistically significant unless otherwise mentioned. Differential 148 protein expression was based on the cutoff: P values ≤ 0.05 , $|\log_2 FC| > 0.25$. Plotting 149

150 was performed with R (version 3.6.3).

151

152 **RESULTS AND DISCUSSION**

153 Demographic, clinical, and laboratory characteristics

A total of 144 COVID-19 patients were enrolled in the study. Detailed 154 demographic, clinical, and laboratory characteristics of these patients on admission 155 were provided in Table 1. The median age was 47 years old, and 53.5% of them were 156 male. The severe patients account for 25% (36/144) of the group, were 10 years older 157 than the non-severe patients (55 vs. 45, p < 0.001), and were more likely to have fever 158 symptoms on admission (p = 0.001). Severe patients received higher percentages of 159 treatment in oxygen inhalation (p < 0.001), antibiotics (p = 0.024), glucocorticoid (p < 0.001) 160 161 (0.001), and intravenous gamma immunoglobulin (p < 0.001) than the non-severe 162 patients. These medications may have an impact on the patient blood metabolism and may alter the COVID-19 microenvironment, which unfortunately could not be 163 rigorously examined in the current study due to the small sample size, awaiting future 164 165 investigations. The patients did not exhibit significant difference between severe and non-severe groups in terms of gender unmentioned symptoms on admission, nor other 166 medical treatments (p > 0.05) as listed in Table 1. 167

Based on laboratory test results, a higher percentage of severe patients have 168 elevated levels of serum LDH that are above the upper limit of normal (ULN) value 169 than non-severe patients (58.3% vs. 7.4%, p < 0.001). Likewise, more severe patients 170 also showed higher level of alanine aminotransferase (ALT, p = 0.023), aspartate 171 aminotransferase (AST, p < 0.001), urea (p = 0.004), creatinine (p = 0.029), and 172 creatine kinase (CK, p < 0.001). We then compared their temporal changes at 7-day 173 intervals (Supplementary Table 1). LDH, CK, and creatinine showed continuous 174 175 decrease in the sera of severe patients, while only serum LDH showed a continuous 176 decrease in non-severe patients.

177 A Cox regression model was applied to evaluate the prognostic value of these 178 indicators (Supplementary Table 2). In the Cohort 1, LDH is the only indicator with 179 discrimination ability (p < 0.001) in the multivariate analysis, although LDH, AST, 180 and CK were determined in the univariate analysis with statistical significance (p <181 0.001). We further validated the value of serum LDH in Cohort 2 and the data showed 182 significant discrimination (p = 0.032), suggesting that serum LDH could be a useful 183 prognostic biomarker.

184

185

Temporal characteristics of Serum LDH in COVID-19 patients

We then assessed the effect of age and sex on the temporal serum LDH expression. 186 COVID-19 patients older than 60 years showed a higher serum LDH expression 187 throughout the disease course than that in younger patients (Figure 1A), probably due 188 to ageing and underlying diseases. Males expressed higher serum LDH levels than 189 that from females only during the initial hospitalization stage (within the first week) 190 (Figure 1B). Serum LDH levels became comparable between COVID-19 patients and 191 healthy controls (median values: 177 U/L above 60 years old and 152 U/L below 60 192 years old; 154 U/L for males and 158.5 U/L for females) after three weeks. 193

We compared the median values of serum LDH levels from the initial admission stage (1-3 days after admission) and discharge stage (1-3 days before discharge), in a sub-cohort of recovered patients that were discharged by the end of follow-up. (total: n=49; severe: n=13; non-severe: n=36) (Figure 1C). Serum LDH levels were

198 significantly higher in the severe patient group, particularly on admission (p < 0.01).

We analyzed serum LDH isoform expression from 32 patients upon admission
(severe: n=22; non-severe: n=11) (Figure 1D) and found that LDH-2, LDH-4 and
LDH-5 were significantly higher in the sera of severe COVID-19 patients. LDH-1 in
contrast was not dysregulated. LDH-4 and LDH-5 mainly contribute to pyruvate
fermentation under hypoxic conditions, while LDH-1 favors the opposite direction of
the reversible reaction ^[15]. These data suggest anaerobic glycolysis metabolism in
severe patients.

To better understand the temporal dynamics of serum LDH expression over the 206 disease course, we next monitored the serum LDH level from day 1 on admission till 207 day 21 at a 3-day interval (Figure 1E). As to the non-severe patient group, the serum 208 LDH level was slightly higher on admission while declining slowly over the 209 hospitalization period. The serum LDH levels in the severe group comparatively were 210 211 significantly higher upon admission, with a prominent variance range. They dropped 212 significantly from 3rd to 9th day as the patients were taking medical care and by the 21st day fell below the initial serum LDH levels in the non-severe group. 213

214

215 **(**

Classification of low- and high-risk patients based on serum LDH levels

To establish a cohort-specific serum LDH expression threshold as a risk indicator, we took patient severity (severe vs. non-severe) as the dichotomous variable and conducted the receiver operating characteristic (ROC) analysis on the serum LDH expression levels on admission. The area under curve (AUC) was 0.864 (Figure 1F), confirming the discriminative power of serum LDH. The serum LDH level corresponding to the maximum Youden index was determined as 247 U/L, within the threshold to determine serum LDH abnormality from past reports (240-253.2 U/L)^[13].

Fourteen characteristic patients within the cohort were selected and divided into 223 224 two groups for closer inspection (Figure 1H). The low-risk (LR) group consists of seven non-severe patients with serum LDH expressions below 247 U/L since 225 admission except for one exceptional detection (LR4, 5th day, 306 U/L). The high-risk 226 (HR) group are composed of six severe patients with on admission serum LDH levels 227 above 247 U/L, and one severe patient with serum LDH levels below the threshold 228 229 throughout hospitalization (HR1). We attribute this to the relatively late first sampling timepoint (8th day), given that serum LDH levels from all the patients started at a 230 relatively high level and declined over time. Patient HR3 and patient HR7 in 231 particular had exceptionally high serum LDH levels (>450 U/L) upon admission but 232 dropped dramatically within 10 days. We inspected the detailed medical records of the 233 234 14 patients (Table 2). COVID-19 patients with comorbidities including hypertension, chronic HBV infection, and diabetes tend to be severe patients in the HR group, in 235 consistent with the literature [16,17]. 236

237

Quantitative proteomics and metabolomics uncover dysregulated molecules associated with elevated serum LDH

The serum proteomic and metabolomic datasets of the HR and LR group patients 240 were extracted from a collateral project $^{[14]}$. 78.6% (11/14) of the patient sera were 241 sampled during the first week on admission (Table 2), herein representing the stage 242 when serum LDH levels exhibited sharp difference between the LR and HR groups. 243 For the proteomic dataset, the Student's *t*-test highlighted 34 proteins as differentially 244 expressed (p < 0.05) between HR and LR groups (Figure 2A, upper panel), 26 of 245 which were up-regulated. Pathway enrichment analysis using Metascape ^[18] showed 246 these proteins conduct three major immune-related activities including acute 247 inflammatory responses (GO:0002526, p < 0.001), platelet degranulation 248

(GO:0002576, p < 0.001) and regulation of complement cascade (R-HSA-977606, p < 0.001) 249 0.001) (Figure 2A and Supplementary Fig. 2A). Additional analyses using Ingenuity 250 Pathway Analysis (IPA) nominated acute phase response signaling as the most 251 activated immune-related pathway (Supplementary Fig. 2C) in HR patients. These 252 findings were in consistence with the prominent immune behaviors (Supplementary 253 Fig. 1B) as we have previously reported in COVID-19 patients with different severity 254 255 ^[14]. Moreover, blood coagulation (GO: 007596, p < 0.001) was significantly enriched (Supplementary Fig. 2A and 2C). This pathway has been reported to be altered in 256 COVID-19, and associated with interleukin-6 (IL-6))^[19]. Our data showed 257 258 upregulation of acute phase proteins (SAA1, ORM1, AGT, and SERPINA3), complement subunits (C9, C6, and CFI), and LDH subtypes (LDHA and LDHB) in 259 the HR group (Figure 2B). Thirteen of the differentiated proteins were mapped into a 260 261 network wherein key regulators were focused (Figure 2C). Within them, proinflammatory cytokine IL-6 has been widely recognized as a risk factor for COVID-262 19^[19-23] and clinically observed to be positively correlated with serum LDH levels 263 ^[24]. IL-6 can activate TP53, which facilitates cell apoptosis and could enhance LDHA 264 265 expression in blood. Multiple COVID-19 studies involving IL-6 agree with our profiling ^[19,25]. This network also includes CCAAT/enhancer-binding protein beta 266 (CEBPB) which mediates immune and inflammatory responses ^[26], and sterol 267 268 regulatory element binding transcription factor 1 (SREBF1) which regulates lipid metabolisms that has been reported dysregulated in severe COVID-19 patients ^[14]. 269 Taken together, the proteomic difference between LR and HR patients reflected 270 different host responses between the non-severe and severe COVID-19 patients. 271 Of the 34 differentially expressed metabolites listed in Supplementary Fig. 3A, 272 88.2% (30/34) were upregulated, and 52.9% (18/34) were lipids. Within them, 7-273 274 hydroxycholesterol (beta) mediates oxidative stress and induces cell apoptosis. It was elevated during hepatitis B virus (HBV) and hepatitis C virus (HCV) infections ^[27] 275 (Fig 2A and Fig 2B, lower panel). Further calibration and absolute quantification of 276 these lipids would enable in-depth characterization of lipids and their variants. The 277

protein-metabolite joint network generated using IPA (Supplementary Fig. 3B)
proposed two upstream molecules to regulate LDHA expression, including hypoxiainducible factor 1 (HIF1) that mediates hypoxic and inflammatory microenvironments
^[28] and fibronectin 1 (FN1) that involves COVID-19 lung fibrosis ^[29]. The
dysregulated metabolites further consolidate disturbed host responses in association
with serum LDH increase uncovered by the proteomic data.

284

285 Protein and metabolite change in patients with exceptionally high serum LDH

Next, we narrowed our focus to the two patients with exceptionally high serum 286 287 LDH levels on admission (HR3 and HR7, HR outliers), and compared their proteomic patterns with the other HR patients (Figure 3A). 38 proteins including LDHA and 288 LDHB were differentially expressed (p < 0.05, Figure 3A). Metascape pathway 289 enrichment nominated 23 proteins associated with immune system process 290 (GO:0002376, p < 0.001) and 21 proteins associated with metabolic process 291 (GO:0008152, p < 0.001) (Supplementary Fig 4B). The top enriched immune-related 292 293 pathways are the activation of immune response (GO:0002253, p < 0.001) and humoral immunity response (GO:0006959, p < 0.001), while the top enriched 294 metabolic pathway relates to cofactors (R-HSA-89 78934, p < 0.001) (Supplementary 295 296 Fig. 4A). IPA analysis detailed the top metabolic functions as protein ubiquitination pathway and pyruvate fermentation to lactate (Supplementary Fig 4C). Especially, the 297 HIF1 α signaling pathway showed a drastic activation in the HR (outliers) group. As 298

for characteristic proteins in HR (outliers), our data uncovered a dysregulated protein 299 group which includes five up-regulated proteasome subunits, namely PSMA3, 300 PSMA4, PSMA5, PSMB1, and PSMB3 (Figure 3B), possibly due to cell apoptosis ^[30] 301 from organ/tissue damage. They are the mediators of protein ubiquitination and 302 associate with NF- κ B signaling (GO:0038061, p < 0.001). Six of the seven 303 differentially expressed immunoglobulin residues (IGHV3-43, IGHV3-30-5, IGKV1-304 5, IGLV1-36, IGKV1-17, and IGKV2-24) (Supplementary Fig. 5A) were up-regulated 305 in HR (outliers), suggesting that humoral immunity at the point of detection was 306 suppressed or not activated. For the other up-regulated proteins in HR (outliers) 307 (Figure 3B), CES1 is a hepatic protein and its release in blood suggests liver injuries. 308 Protein disulfide-isomerase (P4HB) was reported to up-rise in response to hypoxia 309 ^[31]. GAPDH could enhance HIF activity ^[32] via NF-κB induction activated in hypoxia 310 ^[33], which contributes to heat shock protein 90-alpha (HSP90AA1) upregulation ^[34] to 311 312 form protein complexes with Hif1a. Dipeptidyl peptidase 4 (DPP4), also known as CD26, has been nominated as a potential critical marker in infection susceptibility [35], 313 and its inhibition has been proposed to reduce COVID-19 patient severity ^[36]. DPP4 is 314 also a downstream factor to mark HIF pathway induction ^[37]. Especially, the down-315 regulated protein in HR (outliers) includes CPB2 as a basic carboxypeptidase that 316 suppresses complement system-mediated inflammation^[38]. Its deficiency could lead 317 to accelerated acute lung injuries $^{[39]}$. 84.6% (11/13) of the dysregulated metabolites 318 were lipids (Supplementary Fig. 5B), suggesting disturbed lipid metabolism 319 320 accompanied with serum LDH changes. The network analysis (Supplementary Fig. 5C) further proposed LDH elevation to be associated with HSP90AA1 and 321 322 proteasomes.

323

324

Serum LDH elevation might be driven by tissue injuries and hypoxia

Taking together all the perturbed molecules as highlighted above (Figure 2B and 325 3B), we propose a putative working model for the serum LDH elevation in COVID-326 19 patients (Figure 3C). On the one hand, the inflammation processes triggered by the 327 host immune system induce apoptosis of the infected cells, leading to the release of 328 intracellular LDH into the blood. In high-risk cases, these immune activities result in 329 over-reactive inflammation processes (like "cytokine storm")^[40], thereby releasing 330 higher levels of serum LDH from multiple organs/tissues ^[10]. On the other hand, 331 oxygen homeostasis was disturbed in severe COVID-19 patients ^[12]. Hypoxia 332 reactions occur to accumulate lactate via glycolysis. LDH can balance lactate 333 334 secretion via pyruvate fermentation and a series of metabolic regulation (Supplementary Fig. 4A and 4C) to maintain cellular homeostasis^[41]. The activated 335 NF-kB and HIF pathways in hypoxia conditions could also induce inflammatory 336 responses ^[42]. 337

338

339 CONCLUDING REMARKS

Here we systematically investigated serum LDH elevation in COVID-19 patients. 340 We thoroughly inspected both clinical and molecular profiles of 144 COVID-19 341 patients. We confirmed serum LDH as the best independent risk indicator, and further 342 optimized a threshold of 247 U/L for stratifying COVID-19 patients based on the 343 serum LDH level. Our data showed that the serum LDH declined thereafter, patients 344 with serum LDH levels higher than the threshold on admission are prone to severe 345 346 conditions, hence determined as high-risk (HR) patients, and those lower than the threshold as low-risk (LR) patients. 347

Proteomic differences between LR and HR groups exposed a list of dysregulated 348 host responses. Among them, acute inflammatory responses, platelet degranulation 349 and complement cascade have been reported in previous studies comparing severe and 350 non-severe COVID-19 patients ^[14,43]. Blood coagulation has been highlighted in 351 another report that compares COVID-19 patients with high and low IL-6 levels ^[44]. 352 Immune behaviors including activation of immune response and humoral immune 353 response were further enriched during the intra-comparison within HR patients, 354 suggesting that the immune behaviors are closely related to serum LDH expression. 355 Proteomic profiling also highlighted a list of hypoxia related proteins and functions, 356 including P4HB, DPP4, GAPDH, HSP90AA1, NF-kB and HIF signaling, suggesting 357 that hypoxia might have contributed to elevated LDH. The metabolomic profiling 358 complements findings on the proteomic level and further emphasizes dysregulated 359 360 lipid metabolism. Taken together, we propose that elevation of serum LDH might 361 attribute to inflammation-related tissue injuries and hypoxia-related metabolism.

This study is limited by several factors. Firstly, this is a single-center study with a 362 relatively small patient cohort due to difficulties of sample collection, therefore 363 364 subject to experimental bias. Also, the standard inactivation procedures for COVID-19 serum to minimize the risk of infection may have some impact on the characterized 365 samples. Moreover, proteome data from only 14 individuals were acquired, from 366 which only 2 patients were determined as high-risk group outliers for comparative 367 analysis. We could not obtain the samples from different patients at the identical time 368 points. And due to the small sample size, multiple testing wasn't performed for 369 molecular analyses, therefore the statistical power from the proteomic data has to be 370 interpreted with caution. It is worth noting that serum LDH elevation is not specific to 371 COVID-19 disease ^[45]. Further studies should conduct clinical validation on larger 372 cohorts, and compare the molecular differences including control patients with other 373 374 diseases with similar symptoms. Targeted approaches would also be required to validate our findings for diagnostic purposes. 375

376

377 CONFLICT OF INTERESTS

The research group of T.G. is partly supported by Tencent, Thermo Fisher Scientific, SCIEX, and Pressure Biosciences Inc. T.G. is a shareholder of Westlake Omics Inc. G.R. is an employee of Westlake Omics Inc.

381 ACKNOWLEDGMENTS

382This work was supported by grants from National Key R&D Program of China

383 (No. 2020YFE0202200), National Natural Science Foundation of China (81972492,

21904107, 81672086, 82072333), Zhejiang Provincial Natural Science Foundation for

385 Distinguished Young Scholars (LR19C050001), Hangzhou Agriculture and Society

Advancement Program (20190101A04), Zhejiang Provincial Natural Science

387 Foundation of China (LQ19H100001), Zhejiang Medical and Health Science and

388 Technology Plan (2021KY394), Westlake Education Foundation, and Tencent

389Foundation. We thank Westlake University Supercomputer Center for assistance in

390 data storage and computation.

391 **References**

- [1] Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., ... Cao, B. (2020). Clinical features of patients
 infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)*,
 395(10223), 497-506. doi: 10.1016/S0140-6736(20)30183-5
- [2] Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., . . . Zhang, L. (2020). Epidemiological and
 clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China:
 a descriptive study. *Lancet (London, England), 395*(10223), 507-513. doi: 10.1016/S01406736(20)30211-7
- 399 [3] Hui, D. S.-C., Wong, P.-C., & Wang, C. (2003). SARS: clinical features and diagnosis. *Respirology* 400 (*Carlton, Vic.), 8 Suppl*(Suppl 1), S20-S24. doi: 10.1046/j.1440-1843.2003.00520.x
- 401 [4] Huang, E.-J., Kuo, W.-W., Chen, Y.-J., Chen, T.-H., Chang, M.-H., Lu, M.-C., ... Lee, S.-D. (2006).
 402 Homocysteine and other biochemical parameters in Type 2 diabetes mellitus with
 403 different diabetic duration or diabetic retinopathy. *Clinica Chimica Acta, 366*(1), 293-298.
 404 doi: <u>https://doi.org/10.1016/j.cca.2005.10.025</u>
- 405 [5] Ding, J., Karp, J. E., & Emadi, A. (2017). Elevated lactate dehydrogenase (LDH) can be a marker
 406 of immune suppression in cancer: Interplay between hematologic and solid neoplastic
 407 clones and their microenvironments. *Cancer Biomark, 19*(4), 353-363. doi: 10.3233/cbm408 160336
- 409 [6] Wan, S., Xiang, Y., Fang, W., Zheng, Y., Li, B., Hu, Y., . . . Yang, R. (2020). Clinical features and
 410 treatment of COVID-19 patients in northeast Chongqing. *Journal of medical virology,*411 *92*(7), 797-806. doi: 10.1002/jmv.25783
- 412 [7] Yuan, J., Zou, R., Zeng, L., Kou, S., Lan, J., Li, X., . . . Wang, Z. (2020). The correlation between
 413 viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients.
 414 *Inflammation research : official journal of the European Histamine Research Society ... [et*415 *al.*], 69(6), 599-606. doi: 10.1007/s00011-020-01342-0
- [8] Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., . . . Huang, C.-L. (2020).
 Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. *bioRxiv*.
- [9] Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., . . . Ning, Q. (2020). Clinical and
 immunological features of severe and moderate coronavirus disease 2019. *The Journal of clinical investigation, 130*(5), 2620-2629. doi: 10.1172/JCl137244
- 422 [10] Shi, J., Li, Y., Zhou, X., Zhang, Q., Ye, X., Wu, Z., . . . Zhang, W. (2020). Lactate dehydrogenase
 423 and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested case424 control study. *BMC medicine*, *18*(1), 168-168. doi: 10.1186/s12916-020-01633-7
- [11] Poggiali, E., Zaino, D., Immovilli, P., Rovero, L., Losi, G., Dacrema, A., . . . Terracciano, C. (2020).
 Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. *Clinica chimica acta; international journal of clinical chemistry, 509*, 135-138. doi: 10.1016/j.cca.2020.06.012
- [12] Han, Y., Zhang, H., Mu, S., Wei, W., Jin, C., Tong, C., . . . Gu, G. (2020). Lactate dehydrogenase,
 an independent risk factor of severe COVID-19 patients: a retrospective and observational
 study. *Aging*, *12*(12), 11245-11258. doi: 10.18632/aging.103372
- [13] Henry, B. M., Aggarwal, G., Wong, J., Benoit, S., Vikse, J., Plebani, M., & Lippi, G. (2020). Lactate
 dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality:
 A pooled analysis. *The American Journal of Emergency Medicine, 38*(9), 1722-1726. doi:
 10.1016/j.ajem.2020.05.073
- [14] Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., . . . Guo, T. (2020). Proteomic and Metabolomic
 Characterization of COVID-19 Patient Sera. *Cell*, *182*(1), 59-72.e15. doi:
 10.1016/j.cell.2020.05.032
- 439 [15] Augoff, K., Hryniewicz-Jankowska, A., & Tabola, R. (2015). Lactate dehydrogenase 5: An old
 440 friend and a new hope in the war on cancer. *Cancer Letters, 358*(1), 1-7. doi:
 441 https://doi.org/10.1016/j.canlet.2014.12.035

- [16] Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., . . . Tang, W. (2020). Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. *J Infect, 81*(2), e16-e25. doi: 10.1016/j.jinf.2020.04.021
- [17] Zou, X., Fang, M., Li, S., Wu, L., Gao, B., Gao, H., . . . Huang, J. (2020). Characteristics of Liver
 Function in Patients With SARS-CoV-2 and Chronic HBV Coinfection. *Clin Gastroenterol Hepatol.* doi: 10.1016/j.cgh.2020.06.017
- [18] Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., . . . Chanda, S.
 K. (2019). Metascape provides a biologist-oriented resource for the analysis of systemslevel datasets. *Nat Commun*, *10*(1), 1523. doi: 10.1038/s41467-019-09234-6
- [19] D'Alessandro, A., Thomas, T., Dzieciatkowska, M., Hill, R. C., Francis, R. O., Hudson, K. E., ...
 Hansen, K. C. (2020). Serum Proteomics in COVID-19 Patients: Altered Coagulation and
 Complement Status as a Function of IL-6 Level. *Journal of Proteome Research, 19*(11),
 454 4417-4427. doi: 10.1021/acs.jproteome.0c00365
- [20] Tian, J., Yuan, X., Xiao, J., Zhong, Q., Yang, C., Liu, B., . . . Wang, Z. (2020). Clinical characteristics
 and risk factors associated with COVID-19 disease severity in patients with cancer in
 Wuhan, China: a multicentre, retrospective, cohort study. *The Lancet. Oncology, 21*(7),
 893-903. doi: 10.1016/S1470-2045(20)30309-0
- [21] Liu, F., Li, L., Xu, M., Wu, J., Luo, D., Zhu, Y., ... Zhou, X. (2020). Prognostic value of interleukin6, C-reactive protein, and procalcitonin in patients with COVID-19. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 127*, 104370-104370. doi: 10.1016/j.jcv.2020.104370
- 463 [22] Santa Cruz, A., Mendes-Frias, A., Oliveira, A. I., Dias, L., Matos, A. R., Carvalho, A., ... Silvestre,
 464 R. (2021). Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute
 465 Respiratory Syndrome Coronavirus 2 Pneumonia. *Frontiers in Immunology, 12*, 613422.
 466 doi: 10.3389/fimmu.2021.613422
- 467 [23] Aziz, M., Fatima, R., & Assaly, R. (2020). Elevated interleukin-6 and severe COVID-19: A meta468 analysis. *Journal of medical virology*, *92*(11), 2283-2285. doi: 10.1002/jmv.25948
- [24] Liu, T., Zhang, J., Yang, Y., Ma, H., Li, Z., Zhang, J., . . . Yi, J. (2020). The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. *EMBO molecular medicine*, *12*(7), e12421-e12421. doi: 10.15252/emmm.202012421
- [25] Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., . . . Terrier, B. (2020).
 Impaired type I interferon activity and inflammatory responses in severe COVID-19
 patients. *Science*, *369*(6504), 718-724. doi: 10.1126/science.abc6027
- [26] Kinoshita, S., Akira, S., & Kishimoto, T. (1992). A member of the C/EBP family, NF-IL6 beta,
 forms a heterodimer and transcriptionally synergizes with NF-IL6. *Proc Natl Acad Sci U S A*, *89*(4), 1473-1476. doi: 10.1073/pnas.89.4.1473
- 478 [27] Yoshida, Y., Kodai, S., Takemura, S., Minamiyama, Y., & Niki, E. (2008). Simultaneous
 479 measurement of F2-isoprostane, hydroxyoctadecadienoic acid, hydroxyeicosatetraenoic
 480 acid, and hydroxycholesterols from physiological samples. *Anal Biochem, 379*(1), 105-115.
 481 doi: 10.1016/j.ab.2008.04.028
- [28] Jahani, M., Dokaneheifard, S., & Mansouri, K. (2020). Hypoxia: A key feature of COVID-19
 launching activation of HIF-1 and cytokine storm. *Journal of inflammation (London, England), 17*, 33-33. doi: 10.1186/s12950-020-00263-3
- [29] Xu, J., Xu, X., Jiang, L., Dua, K., Hansbro, P. M., & Liu, G. (2020). SARS-CoV-2 induces
 transcriptional signatures in human lung epithelial cells that promote lung fibrosis. *Respir Res, 21*(1), 182. doi: 10.1186/s12931-020-01445-6
- [30] Weathington, N. M., & Mallampalli, R. K. (2013). New insights on the function of SCF ubiquitin
 E3 ligases in the lung. *Cell Signal, 25*(9), 1792-1798. doi: 10.1016/j.cellsig.2013.05.003
- 490 [31] Ko, H. S., Uehara, T., & Nomura, Y. (2002). Role of ubiquilin associated with protein-disulfide
 491 isomerase in the endoplasmic reticulum in stress-induced apoptotic cell death. *J Biol* 492 *Chem, 277*(38), 35386-35392. doi: 10.1074/jbc.M203412200

- 493 [32] Chiche, J., Pommier, S., Beneteau, M., Mondragon, L., Meynet, O., Zunino, B., . . . Ricci, J. E.
 494 (2015). GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B
 495 lymphomas via NF-kappaB-dependent induction of HIF-1alpha. *Leukemia, 29*(5), 1163496 1176. doi: 10.1038/leu.2014.324
- 497 [33] Li, Y., Yang, L., Dong, L., Yang, Z. W., Zhang, J., Zhang, S. L., . . . Li, S. Q. (2019). Crosstalk
 498 between the Akt/mTORC1 and NF-kappaB signaling pathways promotes hypoxia499 induced pulmonary hypertension by increasing DPP4 expression in PASMCs. *Acta*500 *Pharmacol Sin, 40*(10), 1322-1333. doi: 10.1038/s41401-019-0272-2
- [34] Zuehlke, A. D., Beebe, K., Neckers, L., & Prince, T. (2015). Regulation and function of the human
 HSP90AA1 gene. *Gene, 570*(1), 8-16. doi: 10.1016/j.gene.2015.06.018
- [35] Senapati, S., Kumar, S., Singh, A. K., Banerjee, P., & Bhagavatula, S. (2020). Assessment of risk
 conferred by coding and regulatory variations of TMPRSS2 and CD26 in susceptibility to
 SARS-CoV-2 infection in human. *J Genet, 99*(1). doi: 10.1007/s12041-020-01217-7
- 506
 [36] Solerte, S. B., Di Sabatino, A., Galli, M., & Fiorina, P. (2020). Dipeptidyl peptidase-4 (DPP4)

 507
 inhibition in COVID-19. Acta Diabetol, 57(7), 779-783. doi: 10.1007/s00592-020-01539

 508
 z
- [37] Dang, D. T., Chun, S. Y., Burkitt, K., Abe, M., Chen, S., Havre, P., . . . Dang, L. H. (2008). Hypoxiainducible factor-1 target genes as indicators of tumor vessel response to vascular
 endothelial growth factor inhibition. *Cancer Res, 68*(6), 1872-1880. doi: 10.1158/00085472.can-07-1589
- [38] Leung, L. L. K., & Morser, J. (2018). Carboxypeptidase B2 and carboxypeptidase N in the
 crosstalk between coagulation, thrombosis, inflammation, and innate immunity. *J Thromb Haemost.* doi: 10.1111/jth.14199
- [39] Naito, M., Taguchi, O., Kobayashi, T., Takagi, T., D'Alessandro-Gabazza, C. N., Matsushima,
 Y., . . . Gabazza, E. C. (2013). Thrombin-activatable fibrinolysis inhibitor protects against
 acute lung injury by inhibiting the complement system. *Am J Respir Cell Mol Biol, 49*(4),
 646-653. doi: 10.1165/rcmb.2012-0454OC
- [40] Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020).
 COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet (London, England), 395*(10229), 1033-1034. doi: 10.1016/s0140-6736(20)30628-0
- [41] Lee, D. C., Sohn, H. A., Park, Z. Y., Oh, S., Kang, Y. K., Lee, K. M., . . . Yeom, Y. I. (2015). A lactate induced response to hypoxia. *Cell*, *161*(3), 595-609. doi: 10.1016/j.cell.2015.03.011
- 525 [42] D'Ignazio, L., Bandarra, D., & Rocha, S. (2016). NF-kappaB and HIF crosstalk in immune
 526 responses. *FEBS J, 283*(3), 413-424. doi: 10.1111/febs.13578
- [43] Messner, C. B., Demichev, V., Wendisch, D., Michalick, L., White, M., Freiwald, A., ... Ralser, M.
 (2020). Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19
 Infection. *Cell Systems, 11*(1), 11-24.e14. doi: <u>https://doi.org/10.1016/j.cels.2020.05.012</u>
- [44] D'Alessandro, A., Thomas, T., Dzieciatkowska, M., Hill, R. C., Francis, R. O., Hudson, K. E., . . .
 Hansen, K. C. (2020). Serum Proteomics in COVID-19 Patients: Altered Coagulation and
 Complement Status as a Function of IL-6 Level. *Journal of Proteome Research*. doi: 10.1021/acs.jproteome.0c00365
- [45] Hui, D. S., Wong, P. C., & Wang, C. (2003). SARS: clinical features and diagnosis. *Respirology*,
 8 Suppl(Suppl 1), S20-24. doi: 10.1046/j.1440-1843.2003.00520.x
- 539

538

539

540

Characteristics	Total (N=144)	Non-severe (N=108)	Severe (N=36)	<i>p</i> value	
Age, years					
median (IQR)	QR) 47 (38-56)		55 (48-65)	0.000	
Sex, Male	77 (53.5)	57 (52.8)	20(55.6)	0.772	
Symptoms on Admission					
Fever, %	104 (72.2)	70(64.8)	34 (94.4)	0.001	
Pharyngalgia, %	17 (11.8)	15 (13.9)	2 (5.6)	0.180	
Cough, %	65 (45.1)	47 (43.5)	18 (50.0)	0.499	
Expectoration, %	26 (18.1)	19 (17.6)	7 (19.4)	0.802	
Tiredness, %	16 (11.1) 10 (9.3) 6 (16.7)		6 (16.7)	0.221	
Headache, %	16 (11.1)	9 (8.3)	7 (19.4)	0.066	
Medical Treatment					
Oxygen inhalation, %	97 (67.4)	63 (58.3)	34 (94.4)	0.000	
Antibiotics, %	26 (18.1)	15 (13.9)	11 (30.6)	0.024	
Antivirus, %	144 (100)	108 (100)	36 (100)	1.000	
Glucocorticoid, %	37 (25.7)	13 (12.0)	24 (66.7)	0.000	
Gamma Immunoglobulin, %	33 (22.9)	7 (6.5)	26 (72.2)	0.000	
Laboratorial Indexes					
LDH (ULN) ^a				0.000	
Low or normal	115(79.9)	100 (92.6)	15 (41.7)		
High	29 (20.1)	8 (7.4)	21 (58.3)		
ALT (ULN) ^b				0.023	
Low or normal	130 (90.3)	101 (93.5)	29 (80.6)		
High	14 (9.7)	7 (6.5)	7 (19.4)		
AST (ULN) °				0.000	
Low or normal	125(86.8)	101 (93.5)	24 (66.7)		
High	19 (13.2)	7 (6.5)	12 (33.3)		
Total bilirubin (ULN) ^d				0.422	
Low or normal	122(84.7)	93(86.1)	29 (80.6)		
High	22 (15.3)	15 (13.9)	7 (19.4)		
Total protein (LLN) ^e				0.477	
High or normal	114 (79.2)	87 (80.6)	27 (75.0)		
Low	30 (20.8)	21 (19.4)	9 (25.0)		
Urea (ULN) ^f				0.004	
Low or normal	137 (95.1)	106 (98.1)	31 (86.1)		
High	7 (4.9)	2 (1.9)	5 (13.9)		
Creatinine (ULN) ^g	. /	· /	. /	0.029	

543 Table 1 Clinical characteristics and Laboratorial indexes of COVID-19 patients.

Low or normal	135 (93.8)	104 (96.3)	31 (86.1)	
High	9 (6.3)	4 (3.7)	5 (13.9)	
Creatine kinase (ULN) ^h				0.000
Low or normal	123 (85.4)	99 (91.7)	24 (66.7)	
High	21 (14.6)	9 (8.3)	12 (33.3)	

544 Abbreviations: LDH, Lactate dehydrogenase; AST, aspartate aminotransferase; ALT, Alanine

545 aminotransferase.

^a ULN of LDH for male and female are 285 and 227 U/L, respectively.

^b ULN of ALT for male and female are 50 and 40 U/L, respectively.

 $^{\rm c}$ ULN of AST for male and female are 40 and 35 U/L, respectively.

549 d ULN of total bilirubin is 20.5 μ mol/L.

550 ° LLN of total protein is 65 g/L.

^fULN of urea for male and female are 8 and 8.8 U/L, respectively.

 g ULN of creatinine for male and female are 104 and 84 μ mol/L, respectively.

^b ULN of CK for male and female are 172 and 140 U/L, respectively.

Abbreviations: ULN, upper limit of normal; LLN, lower limit of normal; LDH, Lactate dehydrogenase;

555 AST, aspartate aminotransferase; ALT, Alanine aminotransferase.

Patient Num.	HR1	HR2	HR3	HR4	HR5	HR6	HR7	LR1	LR2	LR3	LR4	LR5	LR6	LR7
Sex	F	М	F	М	М	М	М	М	F	М	F	М	М	М
Age	>60	>60	>60	≤60	≤60	≤60	≤60	>60	≤60	>60	≤60	≤60	≤60	≤60
Days for Admission	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Days for Progression to Severe Stage	2	1	4	0*	1	1	3							
Days for Proteomic Sampling	5	2	2	2	2	1	1	2	6	4	5	4	11	1
Days for Metabolomic Sampling	8	2	2	11	3	1	1	2	1	3	1	1	1	1
Basic Diseases	Left breas t tumo r resect ion	Benign thyroid tumor resection		Hypertension, gout arthritis, hyperuricemia, chronic renal insufficiency for 14 years	High blood pressur e, type 2 diabete s	Chronic viral hepatitis b more than 20 years, hypothyroi dism 5 years	Hepatiti s b virus infectio n more than 10 years ago.	Type 2 diabe tes, hype rlipid emia						Hepatit is b virus infectio n 20 years, type 2 diabete s

556	Table 2 Medical records of tem	poral change associated sever	e patients.
000		ipor ar enange associated sever	parteness

558 *: Patient HR4 was diagnosed as severe before admission to Taizhou Hospital.

Figure 1 Serum LDH expression levels in the study cohort. A-B) Serum LDH 559 expression levels in different time courses grouped by age and sex. *, 0.01<p≤0.05; **, 560 0.005<p≤0.01; ***, 0.001<p≤0.005; ****, p≤0.001. C) Serum LDH expression levels 561 of severe and non-severe patients during the admission and discharge stage. D) 562 Expression of serum LDH isoforms during the admission stage. E) Serum LDH 563 expression levels of severe and non-severe patients in time courses at the 3-day interval. 564 F) Receiver operating characteristic (ROC) of the study cohort when setting LDH 565 expression level cutoff as 247 U/L. G) Individual inspection of 14 patients' LDH 566 expression dynamics. Yellow dash line, Patient HR1; Purple dash line, Patient LR4. 567 568



Figure 2 Molecular differences between low- and high-risk patients. A) Heatmap of
34 differentially expressed proteins and two differentially expressed metabolites. LR,
low-risk patients. HR, high-risk patients. B) Boxplots of nine selected differentially
expressed proteins and two selected differentially expressed metabolites. C) Protein
network including 12 selected differentially expressed proteins.



579 Figure 3 Molecular differences between HR (basic) and HR (outliers) patients. A)

Heatmap of 38 differentially expressed proteins. LR, low-risk patients. HR, high-risk
patients. B) Boxplots of 13 selected differentially expressed proteins. C) Proposed
mechanism for serum LDH elevation in COVID-19 patients.

